[Effect of obzidan and pratsiol therapy on the blood plasma lipid profile and on the high- and low-density lipoprotein apoproteins in hypertension patients].
The effect of an 8-week monotherapy with propranolol and pratsiol on plasma lipid levels and apo-Al and apo-B, apoproteins of high- and low-density lipoproteins (HDLP, LDLP) was studied in 20 patients with second-stage essential hypertension. Propranolol caused no significant changes in plasma lipid spectrum, however it produced a significant rise in apo-Al levels and reduced the cholesterol load index per weight unit of apo-Al in HDLP particles. Pratsiol treatment caused a significant reduction in plasma triglycerides, cholesterol of very-low-density lipoproteins, the cholesterol atherogenic coefficient and the apo-B/apo-Al ratio, and raised the level of HDLP cholesterol. The findings suggest that plasma lipoprotein effects should be taken into account in the choice of hypotensive agents.
D000328:Adult; D001053:Apolipoproteins / Q000097:blood*; D001054:Apolipoproteins A / Q000097:blood*; D001794:Blood Pressure / Q000187:drug effects; D004341:Drug Evaluation; D006801:Humans; D006973:Hypertension / Q000097:blood / Q000188:drug therapy*; D008055:Lipids / Q000097:blood*; D008075:Lipoproteins, HDL / Q000097:blood*; D008077:Lipoproteins, LDL / Q000097:blood*; D008297:Male; D008875:Middle Aged; D011224:Prazosin / Q000627:therapeutic use*; D011433:Propranolol / Q000627:therapeutic use*; D011799:Quinazolines / Q000627:therapeutic use*
D001053:Apolipoproteins; D001054:Apolipoproteins A; D008055:Lipids; D008075:Lipoproteins, HDL; D008077:Lipoproteins, LDL; D011799:Quinazolines; C010681:apolipoprotein LDL, human; D011433:Propranolol; D011224:Prazosin
Vliianie terapii obzidanom i pratsiolom na lipidnyĭ profil' plazmy krovi i apoproteiny lipoproteidov vysokoĭ i nizkoĭ plotnosti u bol'nykh gipertonicheskoĭ bolezn'iu.